LY4100511

DRUG3 trials

Sponsors

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and Company, Eli Lilly and Company

Conditions

HealthyHealthy ParticipantsPlaque Psoriasis

Phase 1

Comparing the Extent to Which Three Different Formulations of LY4100511 (DC-853) Are Made Available in the Body, Alone and in the Presence of a Drug That Reduces Stomach Acid

TerminatedNCT06916143

Eli Lilly and CompanyHealthy Participants

Start: 2025-04-08End: 2025-04-08Updated: 2026-09-09

A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of DC-853 in Healthy Participants

CompletedNCT06937411

Eli Lilly and CompanyHealthy

Start: 2023-02-13End: 2023-10-30Updated: 2025-04-22

Phase 2

A Study of LY4100511 (DC-853) in Adult Participants With Moderate-to-Severe Plaque Psoriasis

CompletedNCT06602219

DICE Therapeutics, Inc., a wholly owned subsidiary of Eli Lilly and CompanyPlaque Psoriasis

Start: 2024-10-25End: 2025-09-04Updated: 2026-08-18